Cornu T.I., Mussolino C., Müller M.C., Wehr C., Kern W.V., Cathomen T. 2021. HIV gene therapy: An update. Hum. Gene Ther. 32, 52‒65.

Article  CAS  PubMed  Google Scholar 

Allers K., Hütter G., Hofmann J., Loddenkemper C., Rieger K., Thiel E., Schneider T. 2011. Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 117 (10), 2791‒2799.

Article  CAS  PubMed  Google Scholar 

Hütter G., Nowak D., Mossner M., Ganepola S., Müssig A., Allers K., Schneider T., Hofmann J., Kücherer C., Blau O., Blau I.W., Hofmann W.K., Thiel E. 2009. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360 (7), 692‒698.

Article  PubMed  Google Scholar 

Peterhoff D. 2023. New case of HIV cure: joined forces of haploidentical stem cells and HLA-mismatched cord blood. Signal Transduct. Target. Ther. 8 (1), 241.

Article  PubMed  PubMed Central  Google Scholar 

Doudna J.A., Charpentier E. 2014. Genome editing. The new frontier of genome engineering with CRISPR/Cas9. Science. 346, 1258096.

Article  PubMed  Google Scholar 

Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. 2013. Multiplex genome engineering using CRISPR/ Cas systems. Science. 339, 819‒823.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho S.W., Kim S., Kim J.M., Kim J.S. 2013. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230‒232.

Article  CAS  PubMed  Google Scholar 

Kang H., Minder P., Park M.A., Mesquitta W.T., Torbett B.E., Slukvin I.I. 2015. CCR5 disruption in induced pluripotent stem cells using CRISPR/Cas9 provides selective resistance of immune cells to CCR5-tropic HIV-1 virus. Mol. Ther. Nucleic Acids. 4, e268.

Article  CAS  PubMed  Google Scholar 

Nerys-Junior A., Braga-Dias L.P., Pezzuto P., Cotta-de-Almeida V., Tanuri A. 2018. Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR/Cas9 when targeting the human CCR5 gene. Genet. Mol. Biol. 41, 167‒179.

Article  PubMed  PubMed Central  Google Scholar 

Cradick T.J., Fine E.J., Antico C.J., Bao G. 2013. CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41, 9584‒9592.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fine E.J., Appleton C.M., White D.E., Brown M.T., Deshmukh H., Kemp M.L., Bao G. 2015. Trans-spliced Cas9 allows cleavage of HBB and CCR5 genes in human cells using compact expression cassettes. Sci. Rep. 5, 10777.

Article  PubMed  PubMed Central  Google Scholar 

Dabrowska M., Czubak K., Juzwa W., Krzyzosiak W.J., Olejniczak M., Kozlowski P. 2018. qEva-CRISPR: A method for quantitative evaluation of CRISPR/Cas-mediated genome editing in target and off-target sites. Nucleic Acids Res. 46, e101.

Article  PubMed  PubMed Central  Google Scholar 

Yu S., Yao Y., Xiao H., Li J., Liu Q., Yang Y., Adah D., Lu J., Zhao S., Qin L., Chen X. 2018. Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR/Cas9 confers resistance to both X4- and R5-tropic human immunodeficiency virus type 1 infection. Hum. Gene Ther. 29, 51‒67.

Article  CAS  PubMed  Google Scholar 

Liu X., Wang M., Qin Y., Shi X., Cong P., Chen Y., He Z. 2018. Targeted integration in human cells through single crossover mediated by ZFN or CRISPR/Cas9. BMC Biotechnol. 18, 66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu L., Yang H., Gao Y., Chen Z., Xie L., Liu Y., Liu Y., Wang X., Li H., Lai W., He Y., Yao A., Ma L., Shao Y., Zhang B., Wang C., Chen H., Deng H. 2017. CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Mol. Ther. 25, 1782‒1789.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu L., Wang J., Liu Y., Xie L., Su B., Mou D., Wang L., Liu T., Wang X., Zhang B., Zhao L., Hu L., Ning H., Zhang Y., Deng K., Liu L., Lu X., Zhang T., Xu J., Li C., Wu H., Deng H., Chen H. 2019. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N. Engl. J. Med. 381 (12), 1240‒1247.

Article  CAS  PubMed  Google Scholar 

Li C., Guan X., Du T., Jin W., Wu B., Liu Y., Wang P., Hu B., Griffin G.E., Shattock R.J., Hu Q. 2015. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J. Gen. Virol. 96, 2381‒2393.

Article  CAS  PubMed  Google Scholar 

Mandal P.K., Ferreira L.M., Collins R., Meissner T.B., Boutwell C.L., Friesen M., Vrbanac V., Garrison B.S., Stortchevoi A., Bryder D., Musunuru K., Brand H., Tager A.M., Allen T.M., Talkowski M.E., Rossi D.J., Cowan C.A. 2014. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell. 15, 643‒652.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ehrke-Schulz E., Schiwon M., Leitner T., Dávid S., Bergmann T., Liu J., Ehrhardt A. 2017. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes. Sci. Rep. 7, 17113.

Article  PubMed  PubMed Central  Google Scholar 

Hosseini Rouzbahani N., Kaviani S., Vasei M., Soleimani M., Azadmanesh K., Nicknam M.H. 2019. Generation of CCR5-ablated human induced pluripotent stem cells as a therapeutic approach for immune-mediated diseases. Iran. J. Allergy Asthma Immunol. 18, 310‒319.

PubMed  Google Scholar 

Vakulskas C.A., Dever D.P., Rettig G.R., Turk R., Jacobi A.M., Collingwood M.A., Bode N.M., McNeill M.S., Yan S., Camarena J., Lee C.M., Park S.H., Wiebking V., Bak R.O., Gomez-Ospina N., Pavel-Dinu M., Sun W., Bao G., Porteus M.H., Behlke M.A. 2018. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216‒1224.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gomez-Ospina N., Scharenberg S.G., Mostrel N., Bak R.O., Mantri S., Quadros R.M., Gurumurthy C.B., Lee C., Bao G., Suarez C.J., Khan S., Sawamoto K., Tomatsu S., Raj N., Attardi L.D., Aurelian L., Porteus M.H. 2019. Human genome-edited hematopoietic stem cells phenotypically correct mucopolysaccharidosis type I. Nat. Commun. 10, 4045.

Article  PubMed  PubMed Central  Google Scholar 

Scharenberg S.G., Poletto E., Lucot K.L., Colella P., Sheikali A., Montine T.J., Porteus M.H., Gomez-Ospina N. 2020. Engineering monocyte/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing. Nat. Commun. 11, 3327.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z., Chen S., Jin X., Wang Q., Yang K., Li C., Xiao Q., Hou P., Liu S., Wu S., Hou W., Xiong Y., Kong C., Zhao X., Wu L., Li C., Sun G., Guo D. 2017. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR/Cas9 protects CD4+ T cells from HIV-1 infection. Cell Biosci. 7, 47.

Article  PubMed  PubMed Central  Google Scholar 

Ye L., Wang J., Beyer A.I., Teque F., Cradick T.J., Qi Z., Chang J.C., Bao G., Muench M.O., Yu J., Levy J.A., Kan Y.W. 2014. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc. Natl. Acad. Sci. U. S. A. 111, 9591‒9596.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X., Bai Y., Cheng X., Kalds P.G.T., Sun B., Wu Y., Lv H., Xu K., Zhang Z. 2018. Efficient SSA-mediated precise genome editing using CRISPR/Cas9. FEBS J. 285, 3362‒3375.

Article  CAS  PubMed  Google Scholar 

Kang X., He W., Huang Y., Yu Q., Chen Y., Gao X., Sun X., Fan Y. 2016. Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. J. Assist. Reprod. Genet. 33, 581‒588.

Article  PubMed  PubMed Central  Google Scholar 

Qi C., Li D., Jiang X., Jia X., Lu L., Wang Y., Sun J., Shao Y., Wei M. 2018. Inducing CCR5Δ32/Δ32 homozygotes in the human jurkat CD4+ cell line and primary CD4+ cells by CRISPR/Cas9 genome-editing technology. Mol. Ther. Nucleic Acids. 12, 267‒274.

Article